Vyrix Pharmaceuticals to Present at Biotech Showcase™ 2015

ENGLEWOOD, Colo., Jan. 8, 2015 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase™ 2015 taking place in San Francisco, CA on January 12-14, 2015.

Jarrett Disbrow, President and Chief Executive Officer of Vyrix, will provide an overview of the Company's business and lead product Zertane™ during his live presentation. He will also be available to participate in one-on-one meetings with investors and prospective partners who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting the company.

About Biotech Showcase™ 2015:
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Vyrix Pharmaceuticals:
Vyrix Pharmaceuticals, Inc., a wholly-owned subsidiary of Ampio Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's health and quality of life. The company's most advanced product is Zertane™ – an oral drug in successful late stage development as a proprietary treatment for premature ejaculation (PE).  PE is a condition that has a major impact on the quality of life for millions of men and their sexual partners. 

About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement:
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contacts for Investors & Media:
Jarrett Disbrow: [email protected]; 720-437-6500, or
April Ramirez: [email protected]; 720-437-6524

Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO

SOURCE Ampio Pharmaceuticals, Inc.

Related Links

http://www.ampiopharma.com